GEMRIC sample, clinical and sociodemographic characteristics
| Characteristic | Value* | Participants† |
|---|---|---|
| Age, yr | 52.83 ± 16.30 | 223 |
| Body mass index, kg/m2 | 25.80 ± 5.46 | 223 |
| Montgomery–Åsberg Depression Rating Scale | ||
| Baseline score | 34.54 ± 8.25 | 221 |
| Post-treatment score | 15.44 ± 11.55 | 219 |
| Change in score | 19.24 ± 12.96 | 218 |
| % Change | 54.50 ± 32.88 | 218 |
| Age at first depression treatment, yr | 36.64 ± 15.63 | 80 |
| Time since first depression treatment, yr | 11.09 ± 11.65 | 80 |
| No. of depressive episodes | 6.08 ± 11.77 | 130 |
| Duration of current episode, wk | 16.25 ± 24.80 | 139 |
| No. of ECT treatments | 11.42 ± 4.83 | 220 |
| ECT electrode placement | — | |
| Right unilateral only | 137 | — |
| Right unilateral ≥ bitemporal | 31 | — |
| Right unilateral ≥ bifrontotemporal | 1 | — |
| Bitemporal only | 32 | — |
| Bitemporal ≥ right unilateral | 2 | — |
| Bifrontotemporal only | 20 | — |
| Medication | — | |
| Antidepressant | 104 | — |
| Selective serotonin reuptake inhibitor | 33 | — |
| Serotonin–norepinephrine reuptake inhibitor | 52 | — |
| Tricyclic antidepressant | 22 | — |
| Antipsychotic | 87 | — |
| Mood stabilizer | 13 | — |
| Lithium | 11 | — |
| Benzodiazepine | 51 | — |